1. Volume 17, Issue 11, Pages 1599-1611 (November 2016)
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open- label, randomised, controlled, phase 3 trial 
Prof Brian I Rini, MD, Prof Arnulf Stenzl, MD, Prof Romauld Zdrojowy, MD, Prof Mikhail Kogan, MD, Mikhail Shkolnik, MD, Prof Stephane Oudard, MD, Prof Steffen Weikert, MD, Prof Sergio Bracarda, MD, Simon J Crabb, PhD, Prof Jens Bedke, MD, Joerg Ludwig, PhD, Dominik Maurer, PhD, Regina Mendrzyk, PhD, Claudia Wagner, PhD, Andrea Mahr, PhD, Jens Fritsche, PhD, Toni Weinschenk, PhD, Steffen Walter, PhD, Alexandra Kirner, PhD, Harpreet Singh-Jasuja, PhD, Carsten Reinhardt, MD, Tim Eisen, FRCP 
The Lancet Oncology 
Volume 17, Issue 11, Pages (November 2016)
DOI: /S (16)
Copyright © 2016 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
*These patient consented to HLA typing but did not undergo the procedure.
The Lancet Oncology  , DOI: ( /S (16) )
Copyright © 2016 Elsevier Ltd Terms and Conditions

3. Figure 2 Overall survival
(A) All patients. (B) Patients with favourable risk. (C) Patients with intermediate risk.
The Lancet Oncology  , DOI: ( /S (16) )
Copyright © 2016 Elsevier Ltd Terms and Conditions

4. Figure 3 Progression-free survival
(A) According to independent and blinded central review. (B) According to investigator assessment.
The Lancet Oncology  , DOI: ( /S (16) )
Copyright © 2016 Elsevier Ltd Terms and Conditions